Prolidase Directly Binds and Activates Epidermal Growth Factor Receptor and Stimulates Downstream Signaling

被引:31
作者
Yang, Lu [1 ]
Li, Yun [1 ,2 ]
Ding, Yi [1 ]
Choi, Kyoung-Soo [3 ]
Kazim, A. Latif [3 ]
Zhang, Yuesheng [1 ]
机构
[1] Roswell Pk Canc Inst, Dept Chemoprevent, Buffalo, NY 14263 USA
[2] Roswell Pk Canc Inst, Dept Urol, Buffalo, NY 14263 USA
[3] Roswell Pk Canc Inst, Dept Cell Stress Biol, Buffalo, NY 14263 USA
基金
美国国家卫生研究院;
关键词
DEFICIENCY; CYCLOOXYGENASE-2; CANCER; EXPRESSION; MICE; INHIBITION; APOPTOSIS; PLASMA; GENE;
D O I
10.1074/jbc.M112.429159
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Prolidase, also known as Xaa-Pro dipeptidase or peptidase D (PEPD), is a ubiquitously expressed cytosolic enzyme that hydrolyzes dipeptides with proline or hydroxyproline at the carboxyl terminus. In this article, however, we demonstrate that PEPD directly binds to and activates epidermal growth factor receptor (EGFR), leading to stimulation of signaling proteins downstream of EGFR, and that such activity is neither cell-specific nor dependent on the enzymatic activity of PEPD. In line with the pro-survival and pro-proliferation activities of EGFR, PEPD stimulates DNA synthesis. We further show that PEPD activates EGFR only when it is present in the extracellular space, but that PEPD is released from injured cells and tissues and that such release appears to result in EGFR activation. PEPD differs from all known EGFR ligands in that it does not possess an epidermal growth factor (EGF) motif and is not synthesized as a transmembrane precursor, but PEPD binding to EGFR can be blocked by EGF. In conclusion, PEPD is a ligand of EGFR and presents a novel mechanism of EGFR activation.
引用
收藏
页码:2365 / 2375
页数:11
相关论文
共 51 条
[1]   PROLIDASE DEFICIENCY - DERMATOLOGICAL MANIFESTATIONS AND SOME ADDITIONAL BIOCHEMICAL STUDIES [J].
ARATA, J ;
UMEMURA, S ;
YAMAMOTO, Y ;
HAGIYAMA, M ;
NOHARA, N .
ARCHIVES OF DERMATOLOGY, 1979, 115 (01) :62-67
[2]   Serum Prolidase Activity and Oxidative Status in Patients With Stage I Endometrial Cancer [J].
Arioz, Dagistan Tolga ;
Camuzcuoglu, Hakan ;
Toy, Harun ;
Kurt, Sefa ;
Celik, Hakim ;
Aksoy, Nurten .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2009, 19 (07) :1244-1247
[3]   Prolidase deficiency associated with hemoglobin O trait and microcytic anemia [J].
Aytug, AF ;
Ergun, T ;
Ratip, S ;
Elcioglu, N ;
Gultepe, M ;
Mercan, E ;
Gurbuz, O .
INTERNATIONAL JOURNAL OF DERMATOLOGY, 2006, 45 (07) :867-868
[4]  
Baselga J, 2002, ONCOLOGIST, V7, P2
[5]   Identifying the structure of the active sites of human recombinant prolidase [J].
Besio, Roberta ;
Alleva, Stefania ;
Forlino, Antonella ;
Lupi, Anna ;
Meneghini, Carlo ;
Minicozzi, Velia ;
Profumo, Antonella ;
Stellato, Francesco ;
Tenni, Ruggero ;
Morante, Silvia .
EUROPEAN BIOPHYSICS JOURNAL WITH BIOPHYSICS LETTERS, 2010, 39 (06) :935-945
[6]   Increased plasma concentration of epidermal growth factor in female patients with non-toxic nodular goitre [J].
Brzezinski, J ;
Lewinski, A .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 1998, 138 (04) :388-393
[7]   Enhanced prolidase activity and decreased collagen content in breast cancer tissue [J].
Cechowska-Pasko, Marzanna ;
Palka, Jerzy ;
Wojtukiewicz, Marek Z. .
INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY, 2006, 87 (04) :289-296
[8]   PROLIDASE DEFICIENCY WITH IMINODIPEPTIDURIA - BIOCHEMICAL INVESTIGATIONS AND 1ST RESULTS OF ATTEMPTED THERAPY [J].
CHARPENTIER, C ;
DAGBOVIE, K ;
LEMONNIER, A ;
LARREGUE, M ;
JOHNSTONE, RAW .
JOURNAL OF INHERITED METABOLIC DISEASE, 1981, 4 (02) :77-78
[9]   Drug therapy: EGFR antagonists in cancer treatment [J].
Ciardiello, Fortunato ;
Tortora, Giampaolo .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (11) :1160-1174
[10]  
Dikic I, 2003, BIOCHEM SOC T, V31, P1178